Trevi Therapeutics, Inc.

NASDAQ: TRVI · Healthcare · Biotechnology

PublicHQ New Haven, CT · New HavenCIK 0001563880Reports USD

#1 of 1,418 Healthcare companies by revenue

EA Score

——

FH 69DQ —GM —SS 57

v0.1 · 35/100 weight · pillars only

↑ Altman-Z, balance-sheet leverage · ↓ Piotroski F, listing tenure

Methodology →

Revenue TTM

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

-$42.8M

Employees

as of 2026-08-08

Market cap

$2.6B

as of 2026-08-08

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Net income-$42.8M-$42.8M2025

Operating income-$49.3M-$49.3M2025

Total assets$193.4M$193.4M2025

Liabilities$10.2M$10.2M2025

Equity$183.2M$183.2M2025

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

What is Trevi Therapeutics, Inc.’s financial profile?

Trevi Therapeutics, Inc. earned -$42.8M in FY2025 net income.

Peers · Healthcare

Structure Therapeutics Inc.——Disc Medicine, Inc.——Kodiak Sciences Inc.——Mineralys Therapeutics, Inc.——Vera Therapeutics, Inc.——Sionna Therapeutics, Inc.——

Neighbors

New Haven →

Veradermics, Incorporated——Biohaven Ltd.——Arvinas, Inc.$262.6M61C Rallybio Corporation$858.0k47D Precipio, Inc.$24.2M69B BioXcel Therapeutics, Inc.$642.0k27D

Key facts

CEOJennifer L. Good

SectorHealthcare

IndustryBiotechnology

HeadquartersNew Haven, CT

ExchangeNASDAQ: TRVI

Employees34

IPO date2019-05-07

Latest filings

10-Q2026-08-06 8-K2026-08-06 8-K2026-06-04 8-K2026-05-05 10-Q2026-05-05 DEF 14A2026-04-21 8-K2026-04-17 8-K2026-03-17

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.